QRCode



Traders/Users: Online

2017/11/03

Omeros Corporation (OMER) and Tenax Therapeutics (TENX): 2 Undervalued Biotechs

By Jorge Aura  -

The biopharmaceutical sector is living a speculation moment. The general feeling among investors is that great advances with the fight against cancer are going to be produced and the existing medication will be improved. Some companies conduct promising studies against cancer. It is speculated that before 10 years we could have a substantial improvement in the partial cure of the most deadly cancers. Meanwhile, other companies are trying to improve the current medication for the orphan indications and critical care market.

There are three companies that are making some spectacular progress in their studies. Omeros Corporation (NASDAQ:OMER) and Tenax Therapeutics Inc (TENX).
In the next article I will write about the reasons to take a speculative position in these companies.
1. Omeros Corporation
According google finance, Omeros Corporation is a biopharmaceutical company that is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery. (Source: Google finance).

Pipeline Portfolio
(Source: Omeros Corporation)

Next Catalyst
Phase 3 program for OMS721 in patients with IgA nephropathy.
-  Revenues about OMIDRIA® in last quarter financials.

Fundamentals Analysis 
Short interest

(SOURCE)

Analyst Research


(SOURCE)

Financials
The company reported the second-quarter financial results on August 8 with the following highlights:
Revenue $17.2MM
Net Income ($14.4MM)
Cash $29.7MM


Chart Analysis

- Rsi marks an oversold. The MACD marks a possible change in upward trend.

2. Tenax Therapeutics Inc
According google finance, Tenax Therapeutics is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect. (Source: Google finance).

Pipeline Portfolio

 (Source: Tenax Therapeutics inc)


Next Catalyst
LEVO-CTS confirmatory trial in cardiac surger.
- NDA news about LEVO-CTS.
- Possible partners or collaborations.

Fundamentals Analysis 
Short interest


(SOURCE)


Analyst Research

(SOURCE)

Financials
The company reported the second-quarter financial results on August 9 with the following highlights:

Revenue$0MM
Net Income($2.98MM)
Cash$8.99MM


Chart Analysis

- The MACD marks a possible change in upward trend.

Disclosure: Jorge Aura has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it.  Jorge Aura has no business relationship with any company whose stock is mentioned in this article.

19 comentarios:

Thanks a lot for the submitted contribution and expressing your opinion! It seems that there are a lot of things to be done ahead.

Both Omeros Corporation and Tenax Therapeutics are considered undervalued biotech stocks due to factors such as market perception, potential growth prospects, and current valuations. These companies have promising pipelines and are poised for future growth. However, as with any investment, it's important for investors to conduct their own research and consider various factors before making any investment decisions.

I don't what you are talking I can't understand your thought. At this time I am so worried about my research. I want a Best Plastic Surgery In Dubai. Please somebody guide me.

The absence of a Kafka EventStore in proof may stem from various considerations, such as architectural decisions, project goals, or technical constraints. It's intriguing to explore the reasoning behind this choice, as it sheds light on the design philosophy and trade-offs made. If you're seeking a skilled and reliable.Iam a professional academic content writer and I also offer synopsis writer online service to the students at an affordable and reasonable price.

The biopharmaceutical sector is a rapidly evolving industry with significant implications, exploring this sector in a dissertation can offer valuable insights and contribute to the existing body of knowledge. When seeking help with dissertation writing, expert assistance can guide students in conducting comprehensive research, analyzing complex data, and presenting their findings effectively.



The biopharmaceutical sector is experiencing a period of immense speculation, particularly regarding advancements in the fight against cancer and the potential improvement of existing medication. Exciting studies are being conducted by various companies, offering hope for the future. Furthermore, the development of Phd Law Thesis Topics relating to cancer showcases the significance of this field for researchers and experts alike. With the possibility of substantial progress within the next decade, there is optimistic anticipation for a partial cure for the most fatal cancers. Additionally, efforts are being made to enhance current medication for the critical care market and orphan indications.

The biopharmaceutical sector is currently going through a speculative phase. This means there's a lot of excitement and interest in the industry, with people making predictions and guesses about its future. It's a time of anticipation and curiosity as the sector evolves and attracts attention for what might come next.

The biopharmaceutical sector is currently experiencing a speculative phase, with heightened anticipation and uncertainty. Investors and stakeholders are closely watching as the industry navigates through this speculative moment, shaping the future of biopharmaceutical advancements.

Undervalued Biotechs are biotechnology companies that are currently valued lower than their worth or potential.

Despite their potential, these undervalued biotechs remained hidden from the spotlight. As time unfolded, their discoveries blossomed, revealing their true worth and forever altering the landscape of medical advancements.

These companies have promising pipelines and are poised for future growth. However, as with any investment, investors need to conduct their own research.

In this moment of uncertainty, laboratories buzz with excitement and anticipation, paving the way for potential breakthroughs that could redefine the future of medicine. The biopharmaceutical sector is on the brink of innovation, making each experiment a step closer to transforming possibilities into realities.

Undervalued biotechs are biotechnology companies or stocks that are perceived to be priced lower than their actual worth or potential in the market. These companies may possess promising drug candidates, innovative technologies.

I apologize for any confusion, but as a language model, I don't have real-time information or opinion. I can provide general information or answer questions based on existing knowledge. If you have any specific questions or need assistance with anything else, feel free to ask!

Omeros is dedicated to advancing medical solutions, while Tenax Therapeutics focuses on innovative therapies. Both companies strive to make significant contributions to the health and well-being of individuals.

As time went on, some undervalued biotechs began to gain recognition and appreciation for their contributions to the field of biotechnology. Their breakthrough therapies and successful clinical trials captured the attention of investors, leading to a surge in interest and investment in the sector.

Take a look at Tenax Therapeutics (TENX). This business is one of the two underappreciated biotechs that are causing a stir in the industry. Investing in Tenax Therapeutics (TENX) may be a wise choice for your portfolio due to the company's potential for growth and the breakthrough medications it is developing.

Both Omeros Corporation (OMER) and Tenax Therapeutics (TENX) represent promising opportunities in the biotech sector. With innovative pipelines and potential breakthrough treatments, these companies are undervalued gems awaiting discovery. Keep an eye on their advancements as they strive to redefine healthcare and potentially deliver substantial returns for investors.

Investors might see potential in these companies due to promising research pipelines or upcoming developments in their products. Investing in undervalued biotechs carries risks but also the potential for significant gains if the companies succeed in bringing valuable treatments to market.